Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards - TipRanks.com
Summary
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single breakthrough treatment can result in tremendous rewards, but failures can be devastating. However, the company has extensive experience in managing large-scale acquisitions, so I’d expect a reasonably streamlined process in aligning research pipelines, navigating any regulatory challenges, and realizing the full scale of Caplyta. However, I’d want to see further investigation into new areas the company can move into as opportunities arise, with strong competition in both the neuroscience and general healthcare sector from rivals such as Pfizer (PFE) and AbbVie (ABBV). With a global supply chain and market, the company has experienced numerous challenges with foreign exchange in recent years, which have hampered EPS growth. With plenty of upside potential and a management team built on a track record of success, I’ve got this as a buy rating and will be watching the coming quarters closely to see how the newest acquisition progresses.